Law360, Washington (August 28, 2012, 3:10 PM ET) -- Sanofi SA subsidiary Genzyme Corp. issued a voluntary recall of 19 lots of its kidney transplant rejection drug Thymoglobulin after discovering some lots of the drug may have stability issues, the company and U.S. Food and Drug Administration announced Monday.
Genzyme said that one Thymoglobulin lot produced negative results during stability testing, prompting a recall of the 25-milligram vials that will affect 52 countries. The affected lots were manufactured using the same raw materials or those of comparable quality, which the company believes is the cause...
Sanofi's Genzyme Pulls 19 Lots Of Thymoglobulin Vials
To view the full article, take a free trial now.
